ImmunoTHerapy Adjacent to Cervical CAncer (ITHACA) study: safety, toxicity and immunological effects of peritumorally delivered immunotherapy in early-stage cervical cancer

2023-505968-11-00 Protocol 14244 Human pharmacology (Phase I) - Other Ended

Start 15 Oct 2024 · End 29 May 2026 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol 14244

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 30
Countries 1
Sites 1

Cervical Cancer

Key facts

Sponsor
Amsterdam UMC
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Female
Therapeutic area
Diseases [C] - Female Urogenital Diseases and Pregnancy Complications [C13], Diseases [C] - Neoplasms [C04]
Trial duration
15 Oct 2024 → 29 May 2026
Decision date (initial)
2024-02-22
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-505968-11-00
ClinicalTrials.gov
NCT06095674

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Cervical Cancer

VersionLevelCodeTermSystem organ class
21.1 LLT 10008229 Cervical cancer 10029104
21.1 LLT 10008233 Cervical cancer stage I 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Amsterdam UMC

Sponsor organisation
Amsterdam UMC
Address
De Boelelaan 1117
City
Amsterdam
Postcode
1081 HV
Country
Netherlands

Scientific contact point

Organisation
Amsterdam UMC
Contact name
Dr. C.H. Mom

Public contact point

Organisation
Amsterdam UMC
Contact name
Dr. C.H. Mom

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ended 30 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ended
Amsterdam UMC
Obstetrics & Gynaecology, De Boelelaan 1117, 1081 HV, Amsterdam

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2024-10-15 2026-05-29 2024-10-15 2026-02-04

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-11-07 Netherlands Acceptable
2024-02-19
2024-02-22
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-05-06 Netherlands Acceptable
2024-02-19
2025-05-06
3 NON SUBSTANTIAL MODIFICATION NSM-2 2025-12-16 Netherlands Acceptable
2024-02-19
2025-12-16